Literature DB >> 14586897

Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence.

Michael Charlton1.   

Abstract

1. Nearly all recipients who are chronically infected with hepatitis C virus (HCV) at the time of liver transplantation will have HCV RNA detectable postoperatively. 2. HCV replication can begin as early as the first postoperative week. 3. HCV levels fall significantly during the anhepatic phase of liver transplantation and continue to fall during the first 12-24 hours posttransplantation. 4. Serum HCV RNA levels typically increase rapidly from the second week posttransplantation and peak by the fourth postoperative month. HCV RNA levels at one year posttransplantation are 10-20 fold greater than pretransplant levels. 5. Corticosteroid treatment for acute cellular rejection is associated with large increases in HCV RNA levels. 6. HCV RNA levels do not appear to vary with choice of calcineurin inhibitor. 7. Early HCV RNA levels are predictive of subsequent histological severity of recurrence. 8. A correlation between early levels of viremia and subsequent allograft injury suggests that initiation of antiviral therapy early in the posttransplant course might be desirable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586897     DOI: 10.1053/jlts.2003.50245

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  10 in total

Review 1.  Recurrent hepatitis C after liver transplant.

Authors:  Andrew S deLemos; Paul A Schmeltzer; Mark W Russo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Impact of donor and recipient race on survival after hepatitis C-related liver transplantation.

Authors:  Jennifer E Layden; Scott J Cotler; Shellee A Grim; Michael J Fischer; Michael R Lucey; Nina M Clark
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

3.  Racial differences in fibrosis progression after HCV-related liver transplantation.

Authors:  Jennifer E Layden; Scott Cotler; Kimberly A Brown; Michael R Lucey; Helen S Te; Sheila Eswaran; Claus Fimmel; Thomas J Layden; Nina M Clark
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

Review 4.  Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus.

Authors:  Yun Ma; Wen-Wei Yan
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

5.  Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.

Authors:  Peter J Horton; Jean Tchervenkov; Jeff S Barkun; Caroline Rochon; Prosanto K Chaudhury; Tammy L Znajda; John B Martinie; Peter Metrakos
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

Review 6.  Alcoholic steatohepatitis: management and prognosis.

Authors:  Jacquelyn J Maher
Journal:  Curr Gastroenterol Rep       Date:  2007-03

7.  Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis.

Authors:  Philip Hilgard; Alisan Kahraman; Nils Lehmann; Cornelia Seltmann; Susanne Beckebaum; R Stefan Ross; Hideo A Baba; Massimo Malago; Christoph E Broelsch; Guido Gerken
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 8.  Challenges of recurrent hepatitis C in the liver transplant patient.

Authors:  Renumathy Dhanasekaran; Roberto J Firpi
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

9.  Management of HCV infection and liver transplantation.

Authors:  Thomas D Schiano; Paul Martin
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

10.  Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients.

Authors:  Mette Juul Nielsen; Ida Falk Villesen; Natasja Stæhr Gudmann; Diana Julie Leeming; Aleksander Krag; Morten Asser Karsdal; Tim Zimmermann; Detlef Schuppan
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.